Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17118421 | ENHANCED PROTEIN STRUCTURE PREDICTION USING PROTEIN HOMOLOG DISCOVERY AND CONSTRAINED DISTOGRAMS | December 2020 | May 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17024656 | METHOD FOR BUILDING PREDICTIVE MODEL OF MICROORGANISM-DERIVED DISSOLVED ORGANIC NITROGEN IN WASTEWATER | September 2020 | February 2025 | Abandon | 53 | 2 | 0 | No | No |
| 16942222 | KINEMATIC MODELING OF BIOCHEMICAL PATHWAYS | July 2020 | April 2025 | Abandon | 56 | 2 | 0 | Yes | No |
| 16940380 | NORMALIZING CHROMOSOMES FOR THE DETERMINATION AND VERIFICATION OF COMMON AND RARE CHROMOSOMAL ANEUPLOIDIES | July 2020 | March 2025 | Allow | 56 | 2 | 0 | Yes | No |
| 16920514 | METHOD AND SYSTEM FOR PERSONALIZED, MOLECULAR BASED HEALTH MANAGEMENT AND DIGITAL CONSULTATION AND TREATMENT | July 2020 | December 2024 | Abandon | 53 | 2 | 1 | Yes | No |
| 16755233 | METHOD AND SYSTEM FOR CHARACTERIZATION OF METABOLISM-ASSOCIATED CONDITIONS, INCLUDING DIAGNOSTICS AND THERAPIES, BASED ON BIOINFORMATICS APPROACH | April 2020 | October 2024 | Abandon | 54 | 2 | 0 | No | No |
| 16638081 | METHOD FOR DETECTING GENE REARRANGEMENT BY USING NEXT GENERATION SEQUENCING | February 2020 | March 2025 | Abandon | 60 | 3 | 0 | No | No |
| 16614588 | METHOD FOR MEASURING ALPHA VALUE OF MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | November 2019 | January 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16669103 | NONINVASIVE PRENATAL DIAGNOSIS OF FETAL TRISOMY BY ALLELIC RATIO ANALYSIS USING TARGETED MASSIVELY PARALLEL SEQUENCING | October 2019 | March 2025 | Abandon | 60 | 3 | 0 | Yes | No |
| 16552653 | ANALYSIS METHOD, INFORMATION PROCESSING APPARATUS, GENE ANALYSIS SYSTEM AND NON-TRANSITORY STORAGE MEDIUM | August 2019 | January 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16504184 | SYSTEM AND METHOD FOR PREDICTING EFFECT OF GENOMIC VARIATIONS ON PRE-MRNA SPLICING | July 2019 | October 2024 | Abandon | 60 | 4 | 0 | Yes | No |
| 16459948 | DETERMINING CELL, TISSUE, OR LESION REPRESENTATIONS IN CELL-FREE DNA | July 2019 | May 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 16446143 | METHODS, APPARATUSES, AND SYSTEMS FOR ANALYZING MICROORGANISM STRAINS IN COMPLEX HETEROGENEOUS COMMUNITIES, DETERMINING FUNCTIONAL RELATIONSHIPS AND INTERACTIONS THEREOF, AND DIAGNOSTICS AND BIOSTATE MANAGEMENT AND BIOSTATE TEMPORAL FORECASTING BASED THEREON | June 2019 | November 2024 | Abandon | 60 | 1 | 1 | No | No |
| 15601282 | INSULIN DELIVERY SYSTEM AND METHODS WITH RISK-BASED SET POINTS | May 2017 | January 2025 | Allow | 60 | 5 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner VASSELL, MEREDITH ABBOTT works in Art Unit 1687 and has examined 14 patent applications in our dataset. With an allowance rate of 28.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.
Examiner VASSELL, MEREDITH ABBOTT's allowance rate of 28.6% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by VASSELL, MEREDITH ABBOTT receive 2.93 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by VASSELL, MEREDITH ABBOTT is 10000 months. This places the examiner in the 0% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +20.8% benefit to allowance rate for applications examined by VASSELL, MEREDITH ABBOTT. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 10.0% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.0% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.